Ameriprise
VIR icon

Ameriprise’s Vir Biotechnology VIR Stock Holding History

Ameriprise’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.09M Sell
205,204
-189,834
-48% -$1.81M ﹤0.01% 3055
2026
Q1 		$3.54M Sell
395,038
-336,269
-46% -$2.68M ﹤0.01% 2658
2025
Q4 		$4.41M Buy
731,307
+537,038
+276% +$3.2M ﹤0.01% 2529
2025
Q3 		$1.11M Sell
194,269
-17,119
-8% -$87.5K ﹤0.01% 3313
2025
Q2 		$1.07M Sell
211,388
-2,347
-1% -$12.6K ﹤0.01% 3246
2025
Q1 		$1.39M Sell
213,735
-5,437
-2% -$48.3K ﹤0.01% 3072
2024
Q4 		$1.61M Sell
219,172
-48,242
-18% -$381K ﹤0.01% 3037
2024
Q3 		$2M Sell
267,414
-40,933
-13% -$356K ﹤0.01% 2917
2024
Q2 		$2.74M Sell
308,347
-14,229
-4% -$136K ﹤0.01% 2716
2024
Q1 		$3.27M Buy
322,576
+9,824
+3% +$100K ﹤0.01% 2621
2023
Q4 		$3.15M Buy
312,752
+1,697
+0.5% +$15.5K ﹤0.01% 2637
2023
Q3 		$2.91M Buy
311,055
+34,902
+13% +$498K ﹤0.01% 2640
2023
Q2 		$6.77M Sell
276,153
-27,386
-9% -$688K ﹤0.01% 2111
2023
Q1 		$7.06M Sell
303,539
-3,386
-1% -$86.6K ﹤0.01% 2059
2022
Q4 		$7.77M Sell
306,925
-270,452
-47% -$6.63M ﹤0.01% 1958
2022
Q3 		$11.1M Buy
577,377
+261,479
+83% +$6.65M ﹤0.01% 1588
2022
Q2 		$8.04M Buy
315,898
+298,022
+1,667% +$6.96M ﹤0.01% 1913
2022
Q1 		$459K Buy
17,876
+3,644
+26% +$108K ﹤0.01% 3518
2021
Q4 		$596K Buy
14,232
+880
+7% +$34.5K ﹤0.01% 3452
2021
Q3 		$581K Sell
13,352
-200
-1% -$8.66K ﹤0.01% 3351
2021
Q2 		$641K Buy
13,552
+105
+0.8% +$4.77K ﹤0.01% 3373
2021
Q1 		$689K Buy
+13,447
New +$725K ﹤0.01% 3291

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ameriprise's VIR Position: Q2 2026 in Review

Ameriprise reduced its Vir Biotechnology (VIR) stake by 48% in Q2 2026, selling an estimated $1.81M and leaving 205,204 shares worth $2.09M. The position accounts for ﹤0.01% of the portfolio, ranked #3055.

Ameriprise first reported a position in VIR in Q1 2021 and has held it in 22 quarters since. The position peaked at $11.1M in Q3 2022. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Ameriprise held 205,204 shares of Vir Biotechnology worth $2.09M as of Q2 2026.
  • Ameriprise sold 189,834 Vir Biotechnology shares in Q2 2026, an estimated $1.81M.
  • Vir Biotechnology made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3055 holding.
  • Ameriprise first reported a position in Vir Biotechnology in Q1 2021 and has held it in 22 quarters since.
  • Ameriprise's Vir Biotechnology position peaked at $11.1M in Q3 2022.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.